| Downgrades | Overweight Eq Weight | X | ||
| Initiated | Buy | X | ||
| Upgrades | In-line Outperform | X | ||
|
$18 $30 |
||||
| Upgrades | Neutral Buy | X | ||
|
$24 $30 |
||||
| Resumed | Neutral | X | ||
| Downgrades | Buy Neutral | X | ||
|
$85 $25 |
||||
| Upgrades | Neutral Overweight | X | ||
| Initiated | Outperform | X | ||
| Upgrades | Underperform In-line | X | ||
| Upgrades | Underperform Neutral | X | ||
|
$53 $46 |
||||
| Upgrades | Eq Weight Overweight | X | ||
|
$70 $104 |
||||
| Downgrades | Neutral Underweight | X | ||
|
$99 $50 |
||||
| Downgrades | Overweight Eq Weight | X | ||
|
$89 $107 |
||||
| Reiterated | Buy | X | ||
|
$100 $140 |
||||
| Upgrades | Eq Weight Overweight | X | ||
|
$74 $89 |
||||
| Downgrades | Overweight Neutral | X | ||
|
$90 $70 |
||||
| Downgrades | In-line Underperform | X | ||
| Initiated | Buy | X | ||
| Initiated | Buy | X | ||
| Upgrades | Perform Outperform | X | ||
| Upgrades | Hold Buy | X | ||
| Upgrades | Underperform In-line | X | ||
| Downgrades | Neutral Underperform | X | ||
|
$159 $154 |
||||
| Reiterated | Overweight | X | ||
|
$140 $225 |
||||
| Upgrades | Hold Buy | X | ||
| Downgrades | Overweight Neutral | X | ||
|
$61 $79 |
||||
| Downgrades | Outperform Neutral | X | ||
|
$57 $80 |
||||
| Initiated | Hold | X | ||
| Downgrades | Outperform Mkt Perform | X | ||
| Initiated | Outperform | X | ||
| Reiterated | Buy | X | ||
|
$28 $32 |
||||
| Reiterated | Buy | X | ||
|
$25 $28 |
||||
NVCR NovoCure Limited
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
